EA2174: A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Enrolling By Invitation
18 years - 99 years
All
Phase
3
10 participants needed
1 Location
Brief description of study
This phase II/III trial studies the usefulness of treatment with nivolumab and ipilimumab in addition to standard of care chemotherapy and radiation therapy in patients with esophageal and gastroesophageal junction adenocarcinoma who are undergoing surgery.
This trial is open to Penn Medicine's Abramson Cancer Center patients only. Please contact the ACC cancer center to see if you qualify.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: adenomcarcinoma
-
Age: 18 years - 99 years
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 834026
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
